Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

SIFCO Stock Surges 109.7% in Three Months: What's Behind the Rally?
SIFCO Stock Surges 109.7% in Three Months: What's Behind the Rally?

SIFCO Industries, Inc.’s SIF investors have been experiencing some short-term gains from the stock of late. Shares of the Cleveland, OH-based manufacturer of forgings, sub-assemblies and machined

Astera Labs vs. KLA: Which Semiconductor Stock Has More Upside?
Astera Labs vs. KLA: Which Semiconductor Stock Has More Upside?

Astera Labs ALAB and KLA Corporation KLAC are major players in the semiconductor industry. While ALAB focuses on high-speed connectivity solutions for AI-driven data centers, KLA provides advanced

Should Investors Buy RYAAY Post a Bullish Fiscal 2026 Traffic Outlook?
Should Investors Buy RYAAY Post a Bullish Fiscal 2026 Traffic Outlook?

European carrier, Ryanair Holdings RYAAY, has unveiled its raised traffic outlook for fiscal 2026, concurrent with its third-quarter fiscal 2026 earnings release on Jan. 26, 2026. As we know, higher

Is MSFT Stock Vulnerable to Rising Capex Pressure From AI Spending?
Is MSFT Stock Vulnerable to Rising Capex Pressure From AI Spending?

Microsoft's MSFT fiscal second-quarter 2026 earnings delivered a familiar combination of strong headline numbers and unsettling fine print, reigniting investor debate over whether the company's

FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug
FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug

Roche RHHBY announced that the FDA has accepted its new drug application (NDA) for giredestrant, an investigational oral therapy, in combination with everolimus, for the treatment of adult patients

Zoom Video Gears Up to Report Q4 Earnings: How to Play the Stock
Zoom Video Gears Up to Report Q4 Earnings: How to Play the Stock

Zoom Video Communications ZM is slated to release fourth-quarter fiscal 2026 results on Feb. 25.Zoom expects its fourth-quarter fiscal 2026 revenues to be between $1.23 billion and $1.235 billion

Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings?
Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings?

We expect investors to focus on the sales performance of CorMedix’s CRMD lead product, DefenCath (taurolidine plus heparin), when the company reports fourth-quarter and full-year 2025 results. The

Adobe Trades 43% Below 52-Week High: Buy, Sell or Hold the Stock?
Adobe Trades 43% Below 52-Week High: Buy, Sell or Hold the Stock?

Adobe ADBE shares closed at $258.61 on Friday, roughly 43% below the 52-week high of $453.26 it hit on March 5, 2025. ADBE shares have plunged 41.8% in the trailing 12-month period, underperforming

Synopsys to Report Q1 Earnings: What's in the Cards for the Stock?
Synopsys to Report Q1 Earnings: What's in the Cards for the Stock?

Synopsys SNPS is scheduled to report first-quarter fiscal 2026 results on Feb. 25, after market close.

Synopsys expects non-GAAP earnings per share between $3.52 and $3.58. The Zacks Consensus

UAL Orders 300 GEnx Engines From GE Aerospace to Power Boeing 787s
UAL Orders 300 GEnx Engines From GE Aerospace to Power Boeing 787s

United Airlines UAL strengthened its long-term partnership with GE Aerospace GE by selecting 300 GEnx engines to power its new Boeing 787 Dreamliners. This order will expand UAL’s 787 fleet to more

The Zacks Analyst Blog Highlights Philip Morris, Lockheed Martin, Danaher and Zeo Energy
The Zacks Analyst Blog Highlights Philip Morris, Lockheed Martin, Danaher and Zeo Energy

For Immediate Release

Chicago, IL – February 23, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and

NVIDIA Highlights This Week of Market Reportage
NVIDIA Highlights This Week of Market Reportage

Monday, February 23rd, 2026After a very eventful week for economic data and amount of Q4 earnings reports, we cool off some to stat a new trading week. We cap off “Mag 7” earnings with Wednesday

GeneDx Holdings Corp. (WGS) Q4 Earnings and Revenues Beat Estimates
GeneDx Holdings Corp. (WGS) Q4 Earnings and Revenues Beat Estimates

GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.7 per share a year ago

ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates
ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates

ImmunityBio (IBRX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.15 per share a year ago. These figures are

Veris Residential (VRE) Q4 FFO and Revenues Top Estimates
Veris Residential (VRE) Q4 FFO and Revenues Top Estimates

Veris Residential (VRE) came out with quarterly funds from operations (FFO) of $0.19 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to FFO of $0.11 per share a

Stepan Co. (SCL) Reports Q4 Loss, Misses Revenue Estimates
Stepan Co. (SCL) Reports Q4 Loss, Misses Revenue Estimates

Stepan Co. (SCL) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of $0.35. This compares to earnings of $0.12 per share a year ago. These figures are adjusted

Lincoln Educational Services Corporation (LINC) Beats Q4 Earnings and Revenue Estimates
Lincoln Educational Services Corporation (LINC) Beats Q4 Earnings and Revenue Estimates

Lincoln Educational Services Corporation (LINC) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.31 per

Ivanhoe Electric (IE) Reports Q4 Loss, Tops Revenue Estimates
Ivanhoe Electric (IE) Reports Q4 Loss, Tops Revenue Estimates

Ivanhoe Electric (IE) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.19 per share a year ago. These figures

Freightos Limited (CRGO) Reports Q4 Loss, Misses Revenue Estimates
Freightos Limited (CRGO) Reports Q4 Loss, Misses Revenue Estimates

Freightos Limited (CRGO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.2 per share a year ago. These figures

Dominion Energy (D) Q4 Earnings and Revenues Surpass Estimates
Dominion Energy (D) Q4 Earnings and Revenues Surpass Estimates

Dominion Energy (D) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.58 per share a year ago. These

Domino's Pizza (DPZ) Lags Q4 Earnings Estimates
Domino's Pizza (DPZ) Lags Q4 Earnings Estimates

Domino's Pizza (DPZ) came out with quarterly earnings of $5.35 per share, missing the Zacks Consensus Estimate of $5.38 per share. This compares to earnings of $4.89 per share a year ago. These

Freshpet (FRPT) Beats Q4 Earnings Estimates
Freshpet (FRPT) Beats Q4 Earnings Estimates

Freshpet (FRPT) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.36 per share a year ago. These figures

AMC Entertainment (AMC) Reports Q4 Loss, Tops Revenue Estimates
AMC Entertainment (AMC) Reports Q4 Loss, Tops Revenue Estimates

AMC Entertainment (AMC) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.18 per share a year ago. These figures

Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates

Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.96 per share a year ago. These

Should You Buy ANI Pharmaceuticals Stock Before Q4 Earnings?
Should You Buy ANI Pharmaceuticals Stock Before Q4 Earnings?

ANI Pharmaceuticals ANIP is set to report fourth-quarter and full-year 2025 earningson Feb. 27, before the opening bell. The Zacks Consensus Estimate for the quarter’s sales and earnings is pegged